ClinicalTrials.gg
CompletedNCT01497899Updated Nov 19, 2018Results posted

Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

A Phase 2 interventional study of E/C/F/TDF and E/C/F/TAF Placebo in Acquired Immunodeficiency Syndrome and HIV Infections, sponsored by Gilead Sciences. Completed at 41 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-19.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
279
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing cobicistat in Acquired Immunodeficiency Syndrome — none open to participants now, 1 under way, 1 of them phase 3. Cobicistat · Acquired Immunodeficiency Syndrome.

Enrollment
3rd of 16
279 · median 116
Started
2011
with 2 others
Phase 2
Only one
of the 16
Registered
3rd of 16
by date
Lead sponsor
7 of 16
Gilead Sciences

Among the 16 studies testing cobicistat in Acquired Immunodeficiency Syndrome, this one is the 3rd largest by enrollment, is one of 3 that started in 2011, is the only one in phase 2, and was the 3rd registered.

Acquired Immunodeficiency Syndrome

3,037 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

Browse Acquired Immunodeficiency Syndrome studies →

Open to participants now

None of the 16 studies testing cobicistat in Acquired Immunodeficiency Syndrome is open now. The open studies under Acquired Immunodeficiency Syndrome, anywhere →

About cobicistat

Cobicistat: first FDA approval 2012 (STRIBILD), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 198 Acquired Immunodeficiency Syndrome studies recruiting now, 118 (60%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing cobicistat in Acquired Immunodeficiency Syndrome as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya®; E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (Stribild®; E/C/F/TDF) FDC in HIV-1 infected, antiretroviral treatment-naive adults.

03

Conditions studied

  • Acquired Immunodeficiency Syndrome
  • HIV Infections

Keywords

  • HIV-1
  • HIV
  • Treatment-Naive
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Ability to understand and sign a written form
  • Plasma 1 RNA levels ≥ 5,000 copies/mL
  • No prior use of any approved or experimental anti-HIV drug for any length of time
  • Screening genotype report must show sensitivity to TDF and emtricitabine (FTC)
  • Normal
  • Adequate renal function: Estimated ≥ 70 mL/min according to the formula
  • Hepatic transaminases ≤ 2.5 x (ULN)
  • Total ≤ 1.5 mg/dL, or normal direct bilirubin
  • Adequate hematologic function
  • > 50 cells/µL
  • Serum amylase ≤ 5 x ULN
  • Normal thyroid-stimulating hormone (TSH)
  • Females of must have a negative serum pregnancy test
  • Females of childbearing potential must agree to utilize highly effective methods from screening throughout the duration of study treatment and for 30 days following the last dose of study drugs
  • Female subjects who utilize hormonal contraceptive as one of their birth control methods must have used the same method for at least three months prior to study dosing
  • Female subjects who are must have documentation of cessation of menses for ≥ 12 months and hormonal failure
  • Female subjects who have stopped menstruating for ≥ 12 months but do not have documentation of ovarian hormonal failure must have a serum follicle stimulating hormone (FSH) level test at screening
  • Male subjects must agree to utilize a highly effective method of contraception during heterosexual intercourse throughout the study period and for 90 days following discontinuation of medicinal product
  • Age ≥ 18 years
  • ≥ 1 year

Key Exclusion Criteria:

  • New AIDS-defining condition diagnosed within the 30 days prior to screening
  • surface Antigen positive
  • Antibody positive
  • Proven acute hepatitis in the 30 days prior to study entry
  • Subjects experiencing decompensated cirrhosis
  • Females who are breastfeeding
  • Positive serum pregnancy test (female of childbearing potential)
  • Have an implanted defibrillator or pacemaker
  • Receiving ongoing therapy with any of the disallowed medications, including drugs not to be used with elvitegravir and cobicistat
  • Have been treated with therapies or chemotherapeutic agents within 3 months of study screening, or expected to receive these agents or systemic during the study
  • Current alcohol or substance
  • History of or ongoing (including untreated carcinoma in-situ) other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma or resected, non-invasive cutaneous squamous carcinoma
  • Active, serious infections (other than HIV 1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to Baseline
  • Participation in any other clinical trial without prior approval is prohibited while participating in this trial
  • Medications for use with emtricitabine or tenofovir disoproxil fumarate
  • Any known allergies to the of E/C/F/TAF or E/C/F/TDF FDC tablets
  • Any other clinical condition or prior therapy that would make the subject unsuitable for the study or unable to comply with the dosing requirements

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
279 participants (actual)

Study arms

  • Experimental
    E/C/F/TAF

    E/C/F/TAF plus E/C/F/TDF placebo for at least 48 weeks

    Drug: E/C/F/TAF · Drug: E/C/F/TDF Placebo

  • Active comparator
    E/C/F/TDF

    E/C/F/TDF plus E/C/F/TAF placebo for at least 48 weeks

    Drug: E/C/F/TDF · Drug: E/C/F/TAF Placebo

  • Experimental
    E/C/F/TAF Open-Label

    Following study unblinding, participants from the E/C/F/TAF and E/C/F/TDF arms may have the option to receive E/C/F/TAF during an open-label extension phase. Also, participants who are actively participating in a Gilead-sponsored study of cobicistat-boosted darunavir plus nucleoside/nucleotide reverse transcriptase inhibitors (NRTI) who have reached the protocol-defined secondary endpoint (Week 48) and remain virologically suppressed are eligible to participate and receive E/C/F/TAF in this open-label extension phase.

    Drug: E/C/F/TAF

Interventions

  • DrugE/C/F/TDF

    150/150/200/300 mg FDC tablet administered orally once daily

    Also known as: Stribild®

  • DrugE/C/F/TAF Placebo

    Tablet administered orally once daily

  • DrugE/C/F/TAF

    Drug pages: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide

    150/150/200/10 mg FDC tablet administered orally once daily

    Also known as: Genvoya®

  • DrugE/C/F/TDF Placebo

    Tablet administered orally once daily

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

  2. Change From Baseline in log10 HIV-1 RNA at Weeks 24 and 48

    Time frame: Baseline; Weeks 24 and 48

  3. Change From Baseline in CD4+ Cell Count at Weeks 24 and 48

    Time frame: Baseline; Weeks 24 and 48

07

Results

Posted Jan 8, 2016
Limitations and caveats
There were no limitations affecting the analysis or results.

Participant flow

Participants were enrolled at study sites in the United States and Puerto Rico. The first participant was screened on 28 December 2011. The last study visit occurred on 22 August 2016.

Double-Blind Phase
Participant flow — Double-Blind Phase
MilestoneE/C/F/TAFE/C/F/TDFD/C/F/TAF to Open-Label E/C/F/TAFDRV+COBI+TVD to Open-Label E/C/F/TAF
Started1135800
Completed1075300
Not completed6500
Withdrew: Randomized but not treated1000
Withdrew: Adverse event1000
Withdrew: Lack of efficacy0100
Withdrew: Investigator's discretion1000
Withdrew: Withdrew consent0100
Withdrew: Lost to follow-up3200
Withdrew: Subject non-compliance0100
Open-Label Extension Phase
Participant flow — Open-Label Extension Phase
MilestoneE/C/F/TAFE/C/F/TDFD/C/F/TAF to Open-Label E/C/F/TAFDRV+COBI+TVD to Open-Label E/C/F/TAF
Started105537038
Completed86466133
Not completed19795
Withdrew: Adverse event1000
Withdrew: Death1000
Withdrew: Withdrew consent8320
Withdrew: Pregnancy0110
Withdrew: Protocol violation0010
Withdrew: Lost to follow-up9355

Outcome measures

PrimaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24
percentage of participantsE/C/F/TAFE/C/F/TDF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 2488.489.7
Statistical analysis
  • E/C/F/TAF vs E/C/F/TDF · Cochran-Mantel-Haenszel · p = 0.58 · Difference in percentages: -2.9 · 95% CI -13.5 to 7.7Difference in percentages of virologic success and its 95% confidence interval (CI) were calculated based on baseline HIV-1 RNA stratum-adjusted Mantel-Haenszel (MH) proportion.
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48
percentage of participantsE/C/F/TAFE/C/F/TDF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 4888.487.9
SecondaryChange From Baseline in log10 HIV-1 RNA at Weeks 24 and 48
Time frame:
Baseline; Weeks 24 and 48
Reported as:
Mean · log10 copies/mL
Change From Baseline in log10 HIV-1 RNA at Weeks 24 and 48
log10 copies/mLE/C/F/TAFE/C/F/TDF
Baseline4.63 ± 0.5724.69 ± 0.577
Change at Week 24-3.20 ± 0.654-3.26 ± 0.606
Change at Week 48-3.22 ± 0.606-3.33 ± 0.572
SecondaryChange From Baseline in CD4+ Cell Count at Weeks 24 and 48
Time frame:
Baseline; Weeks 24 and 48
Reported as:
Mean · cells/uL
Change From Baseline in CD4+ Cell Count at Weeks 24 and 48
cells/uLE/C/F/TAFE/C/F/TDF
Baseline404 ± 181.6394 ± 209.6
Change at Week 24165 ± 115.6179 ± 127.7
Change at Week 48177 ± 144.1204 ± 120.4

Adverse events

Collected over Up to 186.2 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
E/C/F/TAF—12/112 (10.7%)91/112 (81.3%)
E/C/F/TDF—3/58 (5.2%)48/58 (82.8%)
All E/C/F/TAF—35/273 (12.8%)215/273 (78.8%)
Most frequent serious events
Showing 10 of 61
Most frequent serious events
EventE/C/F/TAFE/C/F/TDFAll E/C/F/TAF
DepressionPsychiatric disorders1/1122/583/273
Suicidal ideationPsychiatric disorders1/1122/582/273
Large intestine perforationGastrointestinal disorders0/1121/580/273
Clostridium difficile colitisInfections and infestations0/1121/580/273
Road traffic accidentInjury, poisoning and procedural complications0/1121/580/273
Thoracic vertebral fractureInjury, poisoning and procedural complications0/1121/580/273
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/1121/580/273
AppendicitisInfections and infestations0/1120/584/273
Bipolar disorderPsychiatric disorders1/1120/583/273
Acute myocardial infarctionCardiac disorders1/1120/582/273
Most frequent other events
Showing 10 of 39
Most frequent other events
EventE/C/F/TAFE/C/F/TDFAll E/C/F/TAF
NauseaGastrointestinal disorders25/1127/5835/273
Upper respiratory tract infectionInfections and infestations17/11212/5860/273
DiarrhoeaGastrointestinal disorders19/1129/5840/273
FatigueGeneral disorders18/1125/5829/273
SyphilisInfections and infestations5/1123/5838/273
Back painMusculoskeletal and connective tissue disorders3/1128/5827/273
HeadacheNervous system disorders11/1128/5826/273
CoughRespiratory, thoracic and mediastinal disorders11/1126/5836/273
BronchitisInfections and infestations7/1123/5833/273
NasopharyngitisInfections and infestations7/1122/5831/273

Baseline characteristics

E/C/F/TAF and E/C/F/TDF arms: participants who were randomized to the Double-Blind Phase and received at least 1 dose of study drug. D/C/F/TAF to E/C/F/TAF and DRV+COBI+TVD to E/C/F/TAF arms: participants who enrolled from Gilead-sponsored Study GS-US-299-0102 in the Open-Label Extension Phase and received at least 1 dose of open-label E/C/F/TAF

Age, Continuous
Age, Continuous(years)E/C/F/TAFE/C/F/TDFD/C/F/TAF to Open-Label E/C/F/TAFDRV+COBI+TVD to Open-Label E/C/F/TAFTotal
Mean35 ± 11.337 ± 10.636 ± 11.237 ± 10.736 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)E/C/F/TAFE/C/F/TDFD/C/F/TAF to Open-Label E/C/F/TAFDRV+COBI+TVD to Open-Label E/C/F/TAFTotal
Female413311
Male108576735267
08

Study locations

41 sites
  • University of Alabama at Birmingham (UAB)
    Birmingham, Alabama 35233, United States
  • Spectrum Medical Group
    Phoenix, Arizona 85012, United States
  • AHF Research Center
    Beverly Hills, California 90211, United States
  • Kaiser Permanente
    Los Angeles, California 90027, United States
  • Peter J. Ruane, MD, Inc.
    Los Angeles, California 90036, United States
  • Anthony Mills MD, Inc
    Los Angeles, California 90069, United States
  • East Bay AIDS Center
    Oakland, California 94609, United States
  • St. Joseph Heritage Healthcare
    Orange, California 92869, United States
  • Stanford University
    Palo Alto, California 94304, United States
  • Kaiser Permanente Medical Group
    Sacramento, California 95825, United States
  • La Playa Medical Group and Clinical Research
    San Diego, California 92103, United States
  • Metropolis Medical
    San Francisco, California 94107, United States
  • Kaiser Permanente Medical Group-Clinical Trials Unit
    San Francisco, California 94118, United States
  • Apex Research, LLC
    Denver, Colorado 80220, United States
  • Dupont Circle Physician's Group
    Washington, District of Columbia 20009, United States
  • Whitman-Walker Health
    Washington, District of Columbia 20009, United States
  • Capital Medical Associates, PC
    Washington, District of Columbia 20036, United States
  • Gary J. Richmond,M.D.,P.A.
    Fort Lauderdale, Florida 33316, United States
  • Wohlfeiler, Piperato and Associates, LLC
    Miami Beach, Florida 33139, United States
  • Orlando Immunology Center
    Orlando, Florida 32803, United States
  • IDOCF/ValuhealthMD, LLC
    Orlando, Florida 32806, United States
  • St. Joseph's Comprehensive Research Institute
    Tampa, Florida 33614, United States
  • Infectious Disease Specialists of Atlanta
    Decatur, Georgia 30033, United States
  • Mercer University Mercer Medicine
    Macon, Georgia 31201, United States
  • Howard Brown Health Center
    Chicago, Illinois 60613, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Be Well Medical Center
    Berkley, Michigan 48072, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Hennepin County Medical Center
    Minneapolis, Minnesota 55415, United States
  • Central West Clinical Research Inc
    Saint Louis, Missouri 63108, United States
  • North Shore University Hospital / Division of Infectious Diseases
    Manhasset, New York 11030, United States
  • ID Consultants, P.A.
    Charlotte, North Carolina 28209, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • University of South Carolina School of Medicine Division of Infectious Disease
    Columbia, South Carolina 29203, United States
  • Southwest Infectious Disease Clinical Research Inc
    Dallas, Texas 75219, United States
  • Tarrant County Infectious Disease Associates
    Fort Worth, Texas 76104, United States
  • Therapeutic Concepts, PA
    Houston, Texas 77004, United States
  • Gordon E. Crofoot, MD., PA
    Houston, Texas 77098, United States
  • DCOL Center for Clinical Research
    Longview, Texas 75605, United States
  • Peter Shalit, M.D.
    Seattle, Washington 98104, United States
  • Clinical Research Puerto Rico
    San Juan, 00909, Puerto Rico
09

References and documents

Publications

  • Sax PE, Zolopa A, Brar I, Elion R, Ortiz R, Post F, Wang H, Callebaut C, Martin H, Fordyce MW, McCallister S. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):52-8. doi: 10.1097/QAI.0000000000000225. PubMed 24872136 ↗

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2011 to primary completion in Oct 2012, 9 months.

Results were first posted in Jan 2016, 3 years 2 months after primary completion. A results delay was requested in Oct 2013.

Of 29 industry-sponsored phase 2 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's 9 months is below that.

Counting every sponsor, half of 86 studies reached it within 36 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2011
First posted
Dec 23, 2011
StartActual
Dec 28, 2011
Primary completionActual
Oct 17, 2012
CompletionActual
Aug 22, 2016
Results delay requested
Oct 21, 2013
Results first posted
Jan 8, 2016
Last update
Nov 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01497899
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Dec 23, 2011
Start date
Dec 28, 2011
Primary completion
Oct 17, 2012
Completion
Aug 22, 2016
Results posted
Jan 8, 2016
Last update
Nov 19, 2018

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide

Start the discussion